Cantor Fitzgerald Maintains Overweight on BridgeBio Pharma, Raises Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer maintains an Overweight rating on BridgeBio Pharma (NASDAQ:BBIO) and raises the price target from $60 to $70.
March 19, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on BridgeBio Pharma and increased the price target from $60 to $70.
The increase in price target by a reputable analyst firm like Cantor Fitzgerald suggests a positive outlook on the stock's future performance. This is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100